Reader TTS

ABSTRACT BACKGROUND: The enzyme arylsulfatase B (ARSB; N-acetylgalactosamine-4-sulfatase) degrades chondroitin-4-sulfate (C4S) and is reduced in malignant colonic and mammary tissues but has

not previously been evaluated in prostate cancer. METHODS: ARSB immunostaining was performed on two tissue microarrays (TMAs) and analyzed by digital image analysis, generating ARSB

H-scores for prevalence and intensity of epithelial, stromal and combined epithelial and stromal immunostaining. Also, paired malignant and normal prostate tissues were analyzed for ARSB

activity, C4S, total sulfated glycosaminoglycans and versican content. The quantities of C4S and of the epidermal growth factor receptor (EGFR) that co-immunoprecipitated with versican were

determined in the normal and malignant paired prostate tissues. RESULTS: Forty-four cases of prostate cancer were paired by age (±5 years), race, Gleason score (in order) and pathological

TNM (tumor, node, metastasis) score. The pairs differed by recurrence vs non-recurrence of elevated PSA at ⩾4 years. When TMA cores were analyzed for ARSB H-score, 18 of the 22 pairs had

lower ARSB H-scores in the recurrent member of the pair, whereas higher initial PSA values were associated with recurrence in only 65% of the paired cases. In a second TMA, Gleason scores 6

and 7 were associated with higher ARSB H-scores than Gleason scores 8 and 9 for stroma, epithelium and stroma and epithelium combined (_P_=0.052, _P_=0.015, _P_<0.0001, respectively) and

were inversely correlated (r=−0.98, −0.97 and −0.99, respectively). In other paired normal and malignant prostate tissues, ARSB activity was significantly higher in the normal tissues, and

C4S and versican values were lower (_P_<0.0001). C4S that co-immunoprecipitated with versican was greater in the malignant than in the normal tissue, whereas total EGFR that

co-immunoprecipitated with versican was reduced. CONCLUSIONS: Study findings suggest that ARSB may be useful as a prognostic biomarker in prostate cancer and that the biological action of

ARSB on chondroitin sulfate may impact upon versican’s effects in the tumor microenvironment. Access through your institution Buy or subscribe This is a preview of subscription content,

access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 4 print issues and online access $259.00 per year only $64.75 per issue Learn

more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS

OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS UPREGULATION OF GALNT7 IN PROSTATE CANCER

MODIFIES _O_-GLYCOSYLATION AND PROMOTES TUMOUR GROWTH Article Open access 01 February 2023 ALTERATIONS IN PROTEIN EXPRESSION AND SITE-SPECIFIC _N_-GLYCOSYLATION OF PROSTATE CANCER TISSUES

Article Open access 05 August 2021 REFORMATION OF THE CHONDROITIN SULFATE GLYCOCALYX ENABLES PROGRESSION OF AR-INDEPENDENT PROSTATE CANCER Article Open access 13 August 2022 REFERENCES *

Glaser JH, Conrad HE . Chondroitin SO4 catabolism in chick embryo chondrocytes. _J Biol Chem_ 1979; 254: 2316–2325. CAS  PubMed  Google Scholar  * deSousa Júnior JF, Nader HB, Dietrich CP .

Sequential degradation of chondroitin sulfate in molluscs. _J Biol Chem_ 1990; 265: 20150–20155. Google Scholar  * Prabhu SV, Bhattacharyya S, Guzman-Hartman G, Macias V, Kajdacsy-Balla A,

Tobacman JK . Extra-lysosomal localization of arylsulfatase B in human colonic epithelium. _J Histochem Cytochem_ 2011; 59: 328–335. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Bhattacharyya S, Solakyildirim K, Zhang Z, Linhardt RJ, Tobacman J . Chloroquine reduces arylsulfatase B activity and increases chondroitin 4-sulfate: Implications for mechanisms of action

and resistance. _Malaria J_ 2009; 8: 303. Article  Google Scholar  * Bhattacharyya S, Solakyildirim K, Zhang Z, Linhardt RJ, Tobacman JK . Cell-bound IL-8 increases in bronchial epithelial

cells following Arylsulfatase B silencing. _Am J Respir Cell Mol Biol_ 2010; 42: 51–61. Article  CAS  PubMed  Google Scholar  * Mitsunaga-Nakatsubo K, Kusunoki S, Kawakami H, Akasaka K,

Akimoto Y . Cell-surface arylsulfatase A and B on sinusoidal endothelial cells, hepatocytes, and Kupffer cells in mammalian livers. _Med Mol Morphol_ 2009; 42: 63–69. Article  CAS  PubMed 

Google Scholar  * Bhattacharyya S, Tobacman JK . Hypoxia reduces arylsulfatase B activity and silencing arylsulfatase B replicates and mediates the effects of hypoxia. _PLoS One_ 2012; 7:

e33250. Article  CAS  PubMed  PubMed Central  Google Scholar  * Bhattacharyya S, Kotlo K, Shukla S, Danziger RS, Tobacman JK . Distinct effects of N-acetylgalactosamine-4-sulfatase and

galactose-6-sulfatase expression on chondroitin sulfate. _J Biol Chem_ 2008; 283: 9523–9530. Article  CAS  PubMed  Google Scholar  * Bhattacharyya S, Tobacman JK . Arylsulfatase B regulates

colonic epithelial cell migration by effects on MMP9 expression and RhoA activation. _Clin Exp Metastasis_ 2009; 26: 535–545. Article  CAS  PubMed  Google Scholar  * Bhattacharyya S,

Tobacman JK . Steroid sulfatase, arylsulfatases A and B, galactose 6-sulfatase, and iduronate sulfatase in mammary cells and effects of sulfated and non-sulfated estrogens on sulfatase

activity. _J Steroid Biochem Mol Biol_ 2007; 103: 20–34. Article  CAS  PubMed  Google Scholar  * Ricciardelli C, Mayne K, Sykes PJ, Wyaymond WA, McCaul K, Marshall VR _et al_. Elevated

stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. _Clin Cancer Res_ 1997; 3: 983–992. CAS  PubMed  Google Scholar  * Ricciardelli C, Mayne K,

Sykes PJ, Raymond WA, McCaul K, Marshall VR _et al_. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. _Clin Cancer Res_ 1998; 4:

963–971. CAS  PubMed  Google Scholar  * Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ . The biological role and regulation of versican levels in cancer. _Cancer Metastasis Rev_

2009; 28: 233–245. Article  PubMed  Google Scholar  * Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB . The interaction of versican with its binding partners. _Cell Res_ 2005; 15: 483–494.

Article  CAS  PubMed  Google Scholar  * Sakko AJ, Ricciardelli C, Mayne K, Suwiwat S, LeBaron RG, Marshall VR _et al_. Modulation of prostate cancer cell attachment to matrix by versican.

_Cancer Res_ 2003; 63: 4786–4791. CAS  PubMed  Google Scholar  * Bhattacharyya S, Feferman L, Tobacman JK Galectin-3 and AP-1 mediate transcriptional effect of Arylsulfatase B

(N-acetylgalactosamine-4-sulfatase) on versican in prostate cancer. AACR 2013: 13-A-4020-AACR. * Schröder FH, Hugosson J, Roobol MJ, ERSPC Investigators. Prostate-cancer mortality at 11

years of follow-up. _N Engl J Med_ 2012; 366: 981–990. Article  PubMed  PubMed Central  Google Scholar  * Makarov DV, Loeb S, Getzenberg RH, Partin AW . Biomarkers for prostate cancer. _Annu

Rev Med_ 2009; 60: 139–151. Article  CAS  PubMed  Google Scholar  * Kajdacsy-Balla A, Geynisman JM, Macias V, Setty S, Nanaji NM, Berman JJ _et al_Cooperative Prostate Cancer Tissue

Resource. Practical aspects of planning, building, and interpreting tissue microarrays: the cooperative prostate cancer tissue resource experience. _J Mol Histol_ 2007; 38: 113–121. Article

  CAS  PubMed  Google Scholar  * Ananthanarayanan V, Deaton RJ, Amatya A, Macias V, Luther E, Kajdacsy-Balla A _et al_. Subcellular localization of p27 and prostate cancer recurrence:

automated digital microscopy analysis of tissue microarrays. _Hum Pathol_ 2011; 42: 873–881. Article  CAS  PubMed  PubMed Central  Google Scholar  * BlyscanTM sulfated GAG assay.

Bio.Bly.VER.03-12March2012int. www.biocolor.co.uk. Accessed 6/11/2012. * Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS _et al_. The roles of versican V1 and V2 isoforms in cell

proliferation and apoptosis. _Mol Biol Cell_ 2005; 16: 1330–1340. Article  CAS  PubMed  PubMed Central  Google Scholar  * Miquel-Serra L, Serra M, Hernández D, Domenzain C, Docampo MJ,

Rabanal RM _et al_. V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. _Lab Invest_ 2006; 86: 889–901. Article  CAS  PubMed  Google Scholar  * Du

WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW _et al_. Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. _PLoS One_

2010; 5: e13828. Article  PubMed  PubMed Central  Google Scholar  * Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y _et al_. Versican/PG-M G3 domain promotes tumor growth and

angiogenesis. _FASEB J_ 2004; 18: 754–756. Article  CAS  PubMed  Google Scholar  * Hernandez D, Miquel-Serra L, Docampo M-J, Marco-Ramell A, Cabrera J, Fabra AS _et al_. V3 versican isoform

alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling. _J Biol Chem_ 2011; 286: 1475–1485. Article  CAS  PubMed  Google Scholar  * Kischel P,

Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S _et al_. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. _Int J Cancer_ 2010;

126: 640–650. Article  CAS  PubMed  Google Scholar  * Rajan R, Vanderslice R, Kapur S, Lynch J, Thompson R, Djakiew D . Epidermal growth factor (EGF) promotes chemomigration of a human

prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. _Prostate_ 1996; 28: 1–9. Article  CAS  PubMed 

Google Scholar  * Perry JE, Grossmann ME, Tindall DJ . Epidermal growth factor induces Cyclin D1 in a human prostate cancer cell line. _Prostate_ 1998; 35: 117–124. Article  CAS  PubMed 

Google Scholar  * Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, Muzi P _et al_. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type

plasminogen activator activity. _Thromb Haemost_ 2005; 93: 964–975. Article  CAS  PubMed  Google Scholar  * Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC _et al_MPS VI

Study Group. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human

N-acetylgalactosamine 4-sulfatase. _Mol Genet Metab_ 2008; 95: 469–475. Article  Google Scholar  Download references ACKNOWLEDGEMENTS We appreciate the contributions of Andrew Hall,

Virgilia Macias, and Klara Valyi-Nagy to the procurement and immunostaining of prostate tissues. Funding was by VA Merit Review and UIC CCTS ULI RR029879 pilot award to JKT. AUTHOR

INFORMATION AUTHORS AND AFFILIATIONS * Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA L Feferman, S Bhattacharyya & J K Tobacman * Jesse Brown VA Medical

Center, Chicago, IL, USA L Feferman, S Bhattacharyya & J K Tobacman * Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA R Deaton, P Gann, G Guzman & A

Kajdacsy-Balla Authors * L Feferman View author publications You can also search for this author inPubMed Google Scholar * S Bhattacharyya View author publications You can also search for

this author inPubMed Google Scholar * R Deaton View author publications You can also search for this author inPubMed Google Scholar * P Gann View author publications You can also search for

this author inPubMed Google Scholar * G Guzman View author publications You can also search for this author inPubMed Google Scholar * A Kajdacsy-Balla View author publications You can also

search for this author inPubMed Google Scholar * J K Tobacman View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to J K

Tobacman. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Feferman,

L., Bhattacharyya, S., Deaton, R. _et al._ Arylsulfatase B (N-acetylgalactosamine-4-sulfatase): potential role as a biomarker in prostate cancer. _Prostate Cancer Prostatic Dis_ 16, 277–284

(2013). https://doi.org/10.1038/pcan.2013.18 Download citation * Received: 03 April 2013 * Revised: 10 May 2013 * Accepted: 26 May 2013 * Published: 09 July 2013 * Issue Date: September 2013

* DOI: https://doi.org/10.1038/pcan.2013.18 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * arylsulfatase B * chondroitin sulfate *

glycosaminoglycan * versican